Opioid Risk: Can a New Algorithm Predict Addiction?
"A groundbreaking study explores how a predictive algorithm could revolutionize opioid prescribing and addiction prevention in primary care."
Chronic pain is a major public health issue, with many patients relying on opioid prescriptions to manage their pain. However, the use of opioids carries a significant risk of developing opioid use disorder (OUD), making it crucial for healthcare providers to carefully assess and mitigate this risk.
Primary care physicians are often the first point of contact for patients seeking pain relief, placing them at the forefront of opioid prescribing. Balancing effective pain management with the need to prevent OUD presents a significant challenge, especially when resources and time are limited.
A recent study published in Health Services Research and Managerial Epidemiology investigates the effectiveness of a predictive algorithm in identifying patients at high risk of OUD. This algorithm incorporates both phenotypic (observable traits) and genotypic (genetic) risk factors to provide a more comprehensive risk assessment.
The Scale of the Crisis
Approximately 105,000 people died from drug overdoses in the United States in 2023, and nearly 80,000 of those deaths involved opioids, or about 76%. The World Health Organization reports that about 60 million people used opioids and that approximately 39.5 million people lived with drug use disorders in 2021. These figures show both the acute mortality burden and the broader scale of opioid use and related disorders.
Clinical Identification and Support
Opioid use disorder is defined as chronic opioid use that causes clinically significant distress or impairment. Evaluation and management therefore focus on identifying a problematic pattern of use and its clinical consequences. Physical dependence is not identical to addiction: the American Psychiatric Association notes that suddenly stopping opioid use after dependence can cause withdrawal symptoms such as whole-body pain, chills, and cramps. Existing approaches to identifying OUD in administrative datasets vary, and a 2026 systematic review is examining their implementation characteristics.
A Long and Changing History
Historical reviews describe the opioid epidemic as the result of developments across opioid use, prescribing, regulation, and illicit supply. The Federal Bureau of Narcotics was founded in 1930, while methadone emerged as a therapy during 1965–1974 and came under increasing federal regulation. Around 2010, the predominant source of heroin in the United States shifted from South America to Mexico as Mexican production increased. Research on the developmental origins of OUD also identifies heterogeneous contributors, including genetic predisposition, prescription-opioid exposure, and environmental risks.
How Does the Predictive Algorithm Work?
The study, led by Maneesh Sharma and colleagues, sought to validate an algorithm that predicts aberrant behavior related to opioid use. This "profile" algorithm uniquely combines phenotypic and genotypic risk factors, offering a comprehensive scoring system to stratify patients according to their risk of developing OUD.
- Phenotypic Factors: These include observable traits and risk factors such as a personal history of alcoholism, illegal drug use, prescription drug misuse, mental health disorders, and age between 16 and 45.
- Genotypic Factors: The algorithm incorporates 11 different single nucleotide polymorphisms (SNPs) that have been linked to opioid abuse, misuse, dependence, or addiction. These SNPs are involved in various neurobiological pathways, including serotonergic, endorphinergic, GABAergic, and dopaminergic pathways.
Research on Brain, Treatment, and Outcomes
Recent reviews examine current trends in OUD, limitations of existing medications, and novel treatment approaches. A clinical perspective on OUD and the brain summarizes reported alterations of brain structure. Long-term studies summarized by Recovery Answers report that mortality risk is at least six times greater among people with OUD than in the general population. Together, these reviews present OUD as a condition involving brain changes, treatment challenges, and serious long-term outcomes.
Why Prevention Has Fallen Short
The CDC defines OUD as a problematic pattern of opioid use that causes significant impairment or distress. The Healing Study describes it as often chronic and recurring, marked by loss of control and continued use despite harmful consequences. These characteristics complicate efforts to treat opioid use as a simple, one-time behavior that can be prevented or corrected through a single intervention. Separately, an analysis by Kolodny reports that pharmaceutical companies deceptively promoted opioids over the past 25 years in ways that were often neither safe nor effective, contributing to the crisis.
Comparing Medication Options
Medication-assisted treatment options include methadone, buprenorphine, and naltrexone. The American Academy of Family Physicians reports that these medications reduce cravings and prevent intoxication if a patient resumes opioid use. A comparison of Suboxone and Vivitrol found that Suboxone performed better in outpatient settings, while the two medications performed similarly on average in inpatient settings. Research on methadone also reports effectiveness in increasing retention among people treated for opioid dependence.
Implications for Primary Care and Beyond
The study's findings suggest that the algorithm can effectively stratify patients in primary care settings according to their risk of OUD. This can help physicians make more informed decisions about opioid prescribing, monitoring, and treatment strategies.
A Treatable but Serious Disorder
The Cleveland Clinic describes OUD as a mental health condition in which opioid use affects a person's health and daily life. It also states that OUD is treatable. A review of long-term opioid-addiction patterns reports that 25% to 50% of study subjects had died within 20 years after study entry, with mortality rates approximately 6 to 20 times higher than expected. These findings combine a treatment-oriented view with evidence of substantial long-term risk.
Forecasts and Expanding Treatment Markets
A 2025 trend analysis forecasts modest increases in the global incidence and disability-adjusted life years associated with opioid-related burden by 2030. The analysis emphasizes the need for sustained, adaptive policies and preventive efforts. Commercial forecasts also project growth in the treatment market: Data Bridge Market Research valued the global OUD market at USD 5.78 billion in 2024 and expects it to reach USD 10.77 billion by 2032, a projected compound annual growth rate of 8.10%. DelveInsight separately estimated the OUD market in the 7MM at approximately USD 2,000 million in 2023 and expects growth through 2034.
A Social and Relapsing Crisis
A social-ecological framework describes the prevalence of opioid use and misuse as having produced a staggering number of deaths over the past two and a half decades. This framing places the crisis within interacting social and environmental contexts rather than treating it solely as an individual medical problem. Medscape characterizes OUD as chronic and relapsing, involving compulsive opioid use and increased overdose risk. The combination of population-level harm and recurrent individual illness makes systemic responses essential.
Personal Journeys Through OUD
A 2023 case report follows one patient's journey from initial prescription-opioid use to escalation into illicit opioids and eventual entry into treatment. The CDC's Rx Awareness campaign presents personal accounts from people affected by prescription opioids. Another CDC-related case-study description says the campaign showcases real stories of people whose lives were negatively affected by prescription opioids. Together, these accounts illustrate how opioid-related harm can unfold across prescribed use, escalation, and treatment while keeping individual experience visible.
By identifying high-risk patients early, clinicians can implement preventative measures such as frequent urine drug testing, alternative pain management therapies, and closer monitoring to reduce the likelihood of OUD development.
While the algorithm shows promise, the researchers emphasize the need for further studies to address limitations such as the wide age range of participants and reliance on ICD codes for OUD diagnosis. Future research should also explore additional objective measures of drug use and address potential barriers to technology adoption, including financial and practice-related challenges.